nivolumab
bms
['sclc', 'nsclc', 'opdivo', 'fierce', 'bmsnews', 'bms']
with a new analysis of opdivo's first-in-class win in neoadjuvant nsclc, is adding one piece of evidence to an ongoing debate over the link between two popular clinical trial endpoints for early-stage cancers. #asco22 
Tweets from the Fierce Life Sciences editorial team